Lv3
250 积分 2020-04-04 加入
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
20天前
已关闭
Harmonizing immunogenicity for AAV and LNP/mRNA modalities: best-practice panels for binding, neutralizing, and cellular assays with pre-existing immunity controls
23天前
已完结
Strategy for streamlining antibody–drug conjugate pharmacokinetic assays
1个月前
已关闭
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
1个月前
已完结
Mitigation of pre-existing immunogenicity in ADA method development
1个月前
已关闭
Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
1个月前
已关闭
Extracellular vesicle proteomics and metabolomics: analytical frameworks and translational insights
1个月前
已关闭
Pharmacokinetics of Inhibitors of Succinyl-CoA:3-Ketoacid CoA Transferase in Sprague–Dawley Rats, and the Effect of a High-Fat Diet
2个月前
已关闭
Accurate quantification of anti-drug antibodies against each unique Fab of a bispecific antibody using an ECL bridging assay
2个月前
已关闭
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
2个月前
已完结
皖公网安备34019202002308
